Skip to main content
SpringerLink
Log in
Book cover

Sexually Transmitted Infections in Adolescence and Young Adulthood pp 279–297Cite as

Human Papillomavirus (HPV)

  • Chapter
  • First Online:

Abstract

Human papillomavirus (HPV) is a double stranded DNA (dsDNA) virus that often causes an asymptomatic infection and clears spontaneously. However, HPV infection may result in genital warts, dysplasia, and squamous cell carcinoma of the head, neck and genitalia. Genital HPV is the most common sexually transmitted infection (STI) in the United States. HPV infection may lead to significant morbidity for both immunocompetent and immunocompromised persons. Immunocompromised persons, including those with human immunodeficiency virus (HIV) infection, are more likely to develop persistent HPV infection and its associated complications. All adolescents and young adults should get the HPV vaccine, ideally prior to initiation of sexual intercourse, in order to prevent infection and the subsequent potential for progression to malignancy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Centers for Disease Control and Prevention. CDC Fact Sheet: incidence, prevalence, and cost of sexually transmitted infections in the United States. 2013. p. 1–4. Available from: https://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf.

  2. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis. 2008;14(6):888–94.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hutter JN, Decker CF. Human papillomavirus infection. Dis Mon. 2016;62(8):294–300.

    Article  PubMed  Google Scholar 

  4. Anderson TA, Schick V, Herbenick D, Dodge B, Fortenberry JD. A study of human papillomavirus on vaginally inserted sex toys, before and after cleaning, among women who have sex with women and men. Sex Transm Infect. 2014;90(7):529–31.

    Article  CAS  PubMed  Google Scholar 

  5. Ryndock EJ, Meyers C. A risk for non-sexual transmission of human papillomavirus? Expert Rev Anti Infect Ther. 2014;12(10):1165–70.

    Article  CAS  PubMed  Google Scholar 

  6. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv. 2006;61(6 Suppl 1):S3–14.

    Article  PubMed  Google Scholar 

  7. Widdice L, Ma Y, Jonte J, Farhat S, Breland D, Shiboski S, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis. 2013;207(8):1286–94.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Workowski KA. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S759–62.

    Article  PubMed  Google Scholar 

  9. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158(5):486–94.

    Article  PubMed  Google Scholar 

  11. Bonanni P, Bechini A, Donato R, Capei R, Sacco C, Levi M, et al. Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines. 2015;3(1):3–12.

    Article  PubMed  PubMed Central  Google Scholar 

  12. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.

    Article  PubMed  Google Scholar 

  13. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):1–9.

    Article  Google Scholar 

  14. Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr. 2016;170(5):445–52.

    Article  PubMed  Google Scholar 

  15. Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: a growing global problem. Int J Appl Basic Med Res. 2016;6(2):84–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1–2):2–10.

    Article  PubMed  CAS  Google Scholar 

  17. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--part B: biological agents. Lancet Oncol. 2009;10(4):321–2.

    Article  PubMed  Google Scholar 

  18. Whiteside MA, Siegel EM, Unger ER. Human papillomavirus and molecular considerations for cancer risk. Cancer. 2008;113(10 Suppl):2981–94.

    Article  CAS  PubMed  Google Scholar 

  19. Nguyen HP, Ramirez-Fort MK, Rady PL. The biology of human papillomaviruses. Curr Probl Dermatol. 2014;45:19–32.

    Article  PubMed  Google Scholar 

  20. Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5(10):1493–506.

    Article  CAS  PubMed  Google Scholar 

  21. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem. 1999;274(9):5810–22.

    Article  CAS  PubMed  Google Scholar 

  22. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol. 1997;71(3):2449–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J. 2012;6:190–7.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68(1):307–13.

    Article  CAS  PubMed  Google Scholar 

  26. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol. 1994;68(7):4262–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Li TT, Zhao LN, Liu ZG, Han Y, Fan DM. Regulation of apoptosis by the papillomavirus E6 oncogene. World J Gastroenterol. 2005;11(7):931–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wallace NA, Galloway DA. Novel functions of the human papillomavirus E6 Oncoproteins. Annu Rev Virol. 2015;2(1):403–23.

    Article  CAS  PubMed  Google Scholar 

  30. Andersson S, Hellstrom AC, Ren ZP, Wilander E. The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas. Med Oncol. 2006;23(1):113–9.

    Article  CAS  PubMed  Google Scholar 

  31. Gormley RH, Kovarik CL. Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep. 2009;6(3):130–8.

    Article  PubMed  Google Scholar 

  32. Ahmed AM, Madkan V, Tyring SK. Human papillomaviruses and genital disease. Dermatol Clin. 2006;24(2):157–65, vi

    Article  CAS  PubMed  Google Scholar 

  33. Virgilio E, Balducci G, Mercantini P, Tozzi F, Ziparo V, Ferri M. Perianal giant condyloma acuminatum of Buschke-Loewenstein: a carcinoma-like condyloma or a condyloma-like carcinoma? ANZ J Surg. 2015;85(5):394–5.

    Article  PubMed  Google Scholar 

  34. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–14.

    Article  PubMed  Google Scholar 

  35. Carifi M, Napolitano D, Morandi M, Dall'Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag. 2015;11:731–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hermann JS, Weckx LY, Monteiro Nurmberger J, Santos Junior GF, Campos Pignatari AC, Nagata Pignatari SS. Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2016;83:94–8.

    Article  PubMed  Google Scholar 

  37. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121(12):1386–91.

    Article  CAS  PubMed  Google Scholar 

  38. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236–47.

    Article  PubMed  Google Scholar 

  39. Mallen-St Clair J, Alani M, Wang MB, Srivastan ES. Human papillomavirus in oropharyngeal cancer: the changing face of a disease. Biochim Biophys Acta. 2016;1866(2):141–50.

    CAS  PubMed  Google Scholar 

  40. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  CAS  PubMed  Google Scholar 

  41. Oriel JD. Natural history of genital warts. Br J Vener Dis. 1971;47(1):1–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Watson RA. Human papillomavirus: confronting the epidemic-a Urologist's perspective. Rev Urol. 2005;7(3):135–44.

    PubMed  PubMed Central  Google Scholar 

  43. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731–8.

    Article  PubMed  Google Scholar 

  44. Massad LS, Xie X, Darragh T, Minkoff H, Levine AM, Watts DH, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol. 2011;118(4):831–9.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100–21.

    Article  PubMed  Google Scholar 

  46. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42.

    Article  PubMed  Google Scholar 

  47. US Department of Health and Human Services: AIDS Info. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf

  48. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The lower Anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32(1):76–115.

    Article  PubMed  Google Scholar 

  49. Nayar R, Wilbur DC. The pap test and Bethesda 2014. “The reports of my demise have been greatly exaggerated.” (after a quotation from mark twain). Acta Cytol. 2015;59(2):121–32.

    Article  CAS  PubMed  Google Scholar 

  50. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–9.

    Article  PubMed  Google Scholar 

  51. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: HPV-associated cancers and precancers 2015. Available from: http://www.cdc.gov/std/tg2015/hpv-cancer.htm.

  52. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35(9):1127–34.

    Article  PubMed  Google Scholar 

  53. Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg. 2016;8(1):41–51.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1–10.

    Article  PubMed  Google Scholar 

  55. New York State Department of Health AIDS Institute. HIV clinical resource: anal dysplasia and cancer. New York: New York State Department of Health; 2007.

    Google Scholar 

  56. Xue R, Elbendary A, Valdebran M, Chaudhari S, Elston D. Pathologic features of anogenital precancerous high-grade squamous intraepithelial lesion (squamous cell carcinoma in situ). J Cutan Pathol. 2016;43(9):735–9.

    Article  PubMed  Google Scholar 

  57. Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6(9):1083–98.

    Article  PubMed  Google Scholar 

  58. Mao C, Balasubramanian A, Yu M, Kiviat N, Ridder R, Reichert A, et al. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer. 2007;120(11):2435–8.

    Article  CAS  PubMed  Google Scholar 

  59. Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol. 2010;34(8):1077–87.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133(3):395–406.

    Article  PubMed  Google Scholar 

  61. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C, et al. Triaging pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol. 2011;121(3):505–9.

    Article  PubMed  Google Scholar 

  62. Schmidt D, Bergeron C, Denton KJ, Ridder R, European CCSG. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011;119(3):158–66.

    Article  PubMed  Google Scholar 

  63. Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, Lorey TS, et al. Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. AIDS. 2012;26(17):2185–92.

    Article  CAS  PubMed  Google Scholar 

  64. Alberts CJ, van Rooijen MS, Prins M, Pawlita M. Schim van der Loeff MF, Waterboer T. HIV is an important risk factor for human papillomavirus types 16 and 18 seropositivity among sexually active men who have sex with men. Sex Transm Dis. 2015;42(3):129–34.

    Article  PubMed  Google Scholar 

  65. Dupin C, Siproudhis L, Henno S, Minjolle S, Arvieux C, Tattevin P. Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients. Dig Liver Dis. 2015;47(5):423–8.

    Article  CAS  PubMed  Google Scholar 

  66. Halloush RA, Akpolat I, Jim Zhai Q, Schwartz MR, Mody DR. Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer. 2008;114(6):474–80.

    Article  CAS  PubMed  Google Scholar 

  67. Larson BK, Mohanty SK, Wu JM, Bose S, Walts AE. ProEx C is a useful ancillary study for grading anal intraepithelial neoplasia alone and in combination with other biomarkers. APMIS. 2016;124(3):175–80.

    Article  CAS  PubMed  Google Scholar 

  68. Kocsis A, Takacs T, Jeney C, Schaff Z, Koiss R, Jaray B, et al. Performance of a new HPV and biomarker assay in the management of hrHPV positive women: subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer. Int J Cancer. 2017;140(5):1119–33.

    Article  CAS  PubMed  Google Scholar 

  69. Kolben TM, Kraft F, Kolben T, Goess C, Semmlinger A, Dannecker C, et al. Expression of Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16 in cervical dysplasia. Future Oncol. 2017;13(2):145–57.

    Article  CAS  PubMed  Google Scholar 

  70. Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S849–55.

    Article  PubMed  Google Scholar 

  71. Steben M, Garland SM. Genital warts. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1063–73.

    Article  PubMed  Google Scholar 

  72. Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol. 1983;147(4):375–8.

    Article  CAS  PubMed  Google Scholar 

  73. Wagenlehner FM, Brockmeyer NH, Discher T, Friese K, Wichelhaus TA. The presentation, diagnosis, and treatment of sexually transmitted infections. Dtsch Arztebl Int. 2016;113(1–02):11–22.

    PubMed  PubMed Central  Google Scholar 

  74. Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol. 2012;5(6):25–36.

    PubMed  PubMed Central  Google Scholar 

  75. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829–46.

    Article  PubMed  Google Scholar 

  76. Weis SE. Current treatment options for management of anal intraepithelial neoplasia. Onco Targets Ther. 2013;6:651–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. NIH US National Library of Medicine. The Anchor Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02135419.

  78. Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2017;5:46–58.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med. 2017;126:116–21.

    Article  PubMed  Google Scholar 

  80. Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope. 2017;127(10):2225–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014;123(3):214–21.

    Article  PubMed  Google Scholar 

  82. Ahmed MM, Connor MP, Palazzolo M, Thompson ME, Lospinoso J, O’Connor P, et al. Effect of high-dose vocal fold injection of cidofovir and bevacizumab in a porcine model. Laryngoscope. 2017;127(3):671–5.

    Article  CAS  PubMed  Google Scholar 

  83. Murono S, Nakanishi Y, Tsuji A, Endo K, Kondo S, Wakisaka N, et al. Intralesional cidofovir injection for recurrent respiratory papillomatosis in Japan. Auris Nasus Larynx. 2016;43(5):541–5.

    Article  PubMed  Google Scholar 

  84. Bryan JT, Buckland B, Hammond J, Jansen KU. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32:34–47.

    Article  CAS  PubMed  Google Scholar 

  85. Cloessner EA, Stokley S, Yankey D, Markowitz LE. Timing of HPV vaccine intervals among United States teens with consideration to the current ACIP schedule and the WHO 2-dose schedule. Hum Vaccin Immunother. 2016;12(6):1375–80.

    Article  PubMed  Google Scholar 

  86. Basu P, Bhatla N, Ngoma T, Sankaranarayanan R. Less than 3 doses of the HPV vaccine – review of efficacy against virological and disease end points. Hum Vaccin Immunother. 2016;12(6):1394–402.

    Article  PubMed  PubMed Central  Google Scholar 

  87. World Health Organization. Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines Schedules 2014. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf.

  88. Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis. 2016;214(5):685–8.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–4.

    PubMed  PubMed Central  Google Scholar 

  90. Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–65.

    Article  PubMed  Google Scholar 

  91. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years – United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–23.

    Google Scholar 

  93. World Health Organization. Human papillomavirus (HPV) and cervical cancer Fact Sheet 2016. Available from: http://www.who.int/entity/mediacentre/factsheets/fs380/en/.

  94. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208–12.

    Article  PubMed  Google Scholar 

  96. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.

    PubMed  Google Scholar 

  97. Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and US safety monitoring plans for nine-valent HPV vaccine. Hum Vaccin Immunother. 2016;12:1406–17.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114(6):1179–88.

    Article  PubMed  Google Scholar 

  99. Choudhury SA, Choudhury NA, Humphrey AD, Berthaud V, Ladson G, Tucker VA, et al. Higher prevalence of human papillomavirus-related cervical precancerous abnormalities in HIV-infected compared to HIV-uninfected women. J Natl Med Assoc. 2016;108(1):19–23.

    PubMed  Google Scholar 

  100. Faust H, Toft L, Sehr P, Muller M, Bonde J, Forslund O, et al. Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559–65.

    Article  CAS  PubMed  Google Scholar 

  101. Kojic EM, Rana AI, Cu-Uvin S. Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert Rev Vaccines. 2016;15(1):105–17.

    Article  CAS  PubMed  Google Scholar 

  102. Nielson CM, Flores R, Harris RB, Abrahamsen M, Papenfuss MR, Dunne EF, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1107–14.

    Article  CAS  PubMed  Google Scholar 

  103. Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis. 2004;190(12):2070–6.

    Article  PubMed  Google Scholar 

  104. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177(2):361–7.

    Article  CAS  PubMed  Google Scholar 

  105. Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther. 2005;18(1):67–76.

    Article  PubMed  Google Scholar 

  106. Mendez-Martinez R, Rivera-Martinez NE, Crabtree-Ramirez B, Sierra-Madero JG, Caro-Vega Y, Galvan SC, et al. Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men. BMC Infect Dis. 2014;14:671.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138(6):453–9.

    Article  PubMed  Google Scholar 

  108. Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31(2):96–9.

    Article  PubMed  Google Scholar 

  109. Eaton L, Kalichman S, Cain D, Cherry C, Pope H, Fuhrel A, et al. Perceived prevalence and risks for human papillomavirus (HPV) infection among women who have sex with women. J Womens Health (Larchmt). 2008;17(1):75–83.

    Article  Google Scholar 

  110. McNair R, Power J, Carr S. Comparing knowledge and perceived risk related to the human papilloma virus among Australian women of diverse sexual orientations. Aust N Z J Public Health. 2009;33(1):87–93.

    Article  PubMed  Google Scholar 

  111. Pelullo CP, Di Giuseppe G, Angelillo IF. Human papillomavirus infection: knowledge, attitudes, and behaviors among lesbian, gay men, and bisexual in Italy. PLoS One. 2012;7(8):e42856.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Reiter PL, McRee AL. HPV infection among a population-based sample of sexual minority women from USA. Sex Transm Infect. 2017;93(1):25–31.

    Article  PubMed  Google Scholar 

  113. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13(5):487–500.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University School of Medicine, Durham, NC, USA

    Amelia B. Thompson

  2. Emory University School of Medicine, Atlanta, GA, USA

    Lisa C. Flowers

Authors
  1. Amelia B. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa C. Flowers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amelia B. Thompson .

Editor information

Editors and Affiliations

  1. Hubert Department of Global Health, Rollins School of Public Health Emory University, Atlanta, GA, USA

    Sophia A. Hussen

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thompson, A.B., Flowers, L.C. (2020). Human Papillomavirus (HPV). In: Hussen, S. (eds) Sexually Transmitted Infections in Adolescence and Young Adulthood. Springer, Cham. https://doi.org/10.1007/978-3-030-20491-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-20491-4_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-20490-7

  • Online ISBN: 978-3-030-20491-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation